| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
Senazodan (HCl) raises myosin ATPase activity and seems to have a direct impact on the dynamics of the actin-myosin cross-bridge [1]. The tonicity increases in response to concentration after using senazodan hydrochloride. Purified cardiac troponin C and myofilaments exhibit enhanced Ca2+ binding when exposed to senazodan (HCl). By decreasing PDE III, senazodan (hydrochloride) also improves the contractility of the papillary muscles in guinea pigs [2]. Senazodan (0.1 nM~0.1 mM) hydrochloride shown a substantial reduction in the superior mesenteric artery's (SMA) contractile response to norepinephrine (NE) following hemorrhagic shock as compared to the normal control group. The pretreatment with senazodan (0.01 mM) hydrochloride inhibited the effects of Ang II and caused a shift in the concentration-response curve of Ca2+ to the right as compared to the Ang II alone group [3].
|
|---|---|
| ln Vivo |
The pressor action of norepinephrine (NE) is lessened by senazodan (0.1~2.0 mg/kg; infusion through left femoral vein cannula) (hydrochloride) [3]. Senazodan (0.1 mg/kg; intravenous injection; hydrochloride) considerably reduced left ventricular end-diastolic pressure (LVEDP) and dramatically increased LVSP, IP, MC, and Lo without significantly changing heart rate [4].
|
| Animal Protocol |
Animal/Disease Models: Wistar rat (200~250 g) [3]
Doses: 0.1~2.0 mg/kg Route of Administration: Left femoral vein intubation infusion Experimental Results: Reduce the pressor effect of norepinephrine (NE). Animal/Disease Models: Rabbit [4] Doses: 0.1 mg/kg Route of Administration: intravenous (iv) (iv)injection Experimental Results: LVSP, IP, MC, and Lo were all Dramatically increased, heart rate had no significant change, and left ventricular end-diastolic pressure (LVEDP) was Dramatically increased. reduce. |
| References |
|
| Additional Infomation |
See also: Senazodan (annotation moved to).
|
| Molecular Formula |
C15H15CLN4O
|
|---|---|
| Molecular Weight |
302.76
|
| Exact Mass |
302.093
|
| CAS # |
98326-33-1
|
| Related CAS # |
Senazodan;98326-32-0
|
| PubChem CID |
123941
|
| Appearance |
Light yellow to yellow solid powder
|
| Boiling Point |
492.4ºC at 760 mmHg
|
| Flash Point |
251.6ºC
|
| LogP |
2.374
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
368
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
NYQCKFLLTCINSJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H14N4O.ClH/c20-15-6-5-14(18-19-15)11-1-3-12(4-2-11)17-13-7-9-16-10-8-13;/h1-4,7-10H,5-6H2,(H,16,17)(H,19,20);1H
|
| Chemical Name |
3-[4-(pyridin-4-ylamino)phenyl]-4,5-dihydro-1H-pyridazin-6-one;hydrochloride
|
| Synonyms |
Senazodan hydrochloride MCI154 MCI 154MCI-154
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~67.5 mg/mL (~222.95 mM)
H2O : ~25 mg/mL (~82.57 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.26 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.26 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3029 mL | 16.5147 mL | 33.0295 mL | |
| 5 mM | 0.6606 mL | 3.3029 mL | 6.6059 mL | |
| 10 mM | 0.3303 mL | 1.6515 mL | 3.3029 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
